Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Somatostatin Analogue Drug Market

Somatostatin Analogue Drug Market Size, Share & Trends Analysis Report, By Drug Type (Octreotide-based Drugs, Lanreotide-based Drugs, Pasireotide-based Drugs, Emerging/Other Analogues), By Indication (Acromegaly, Neuroendocrine Tumors (NETs), Cushing’s Disease, Off-label/Other Indications), By Technology (Microsphere-based Depot Technology, Pre-filled Syringe Systems, Autogel / Deep SC Delivery Systems, Oral Peptide Delivery Technology), Forecast Period (2026-2035)

Published: Jun 2026 | Report Code: OMR2029841 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Somatostatin analogue drug market size was valued at $5.96 billion in 2025 and is projected to reach $10.22 billion by 2035, growing at a CAGR of 5.5% between 2026 and 2035. The market consists of synthetic hormone analogues used to regulate endocrine disorders and manage neuroendocrine tumours. A key driver supporting market growth is the increasing prevalence of chronic diseases and hormonal disorders globally. According to the World Health Organization, noncommunicable diseases account for nearly 74% of deaths worldwide, highlighting the growing burden of long-term medical conditions requiring continuous treatment. Somatostatin analogues are widely used in treating acromegaly, NETs, and Cushing’s disease due to their ability to suppress hormone secretion and control tumour progression. Additionally, advancements in rare disease diagnostics and biologic drug development are accelerating market demand. According to International Federation of Pharmaceutical Manufacturers & Associations, increasing investment in specialty pharmaceuticals and orphan drugs is improving treatment access for rare conditions. Somatostatin analogues are extensively used in oncology and endocrine therapy, particularly in hospitals and specialty clinics, supporting sustained market growth globally.

 Market Dynamics

Rising Prevalence of Endocrine Disorders Driving Market Growth

The increasing incidence of endocrine disorders and neuroendocrine tumours is a major factor driving the somatostatin analogue drug market. These drugs are essential for managing hormone-related conditions by inhibiting excess hormone secretion. According to the U.S. Food and Drug Administration, ongoing approvals of orphan drugs are expanding treatment options for rare diseases, including neuroendocrine tumours. Pharmaceutical companies are investing heavily in clinical research between 2024 and 2026 to develop long-acting and patient-friendly formulations. The rising adoption of sustained-release therapies, combined with increasing healthcare expenditure and awareness, is further accelerating market growth.

 High Treatment Costs and Complex Manufacturing Limiting Market Growth

Despite strong demand, the somatostatin analogue drug market faces challenges related to high treatment costs and complex biologic manufacturing processes. These drugs require advanced peptide synthesis and formulation technologies, increasing production costs. Additionally, strict regulatory requirements and long approval timelines create barriers for new entrants. Supply chain disruptions and pricing pressures further impact market dynamics. Companies are focusing on improving manufacturing efficiency, expanding production capacity, and developing oral alternatives to overcome these challenges. Continuous innovation and cost optimization strategies are expected to support long-term market growth.

Market Segmentation

  • Based on the drug type, the market is segmented into octreotide-based drugs, lanreotide-based drugs, pasireotide-based drugs, and emerging/other analogues.
  • Based on the indication, the market is segmented into acromegaly, neuroendocrine tumours (NETs), Cushing’s disease, and off-label/other indications.
  • Based on the technology, the market is segmented into microsphere-based depot technology, pre-filled syringe systems, auto gel / deep SC delivery systems, and oral peptide delivery technology.

Octreotide-based Drugs Segment Leads the Market

The octreotide-based drugs segment holds a dominant position in the somatostatin analogue drug market due to its extensive use in treating neuroendocrine tumours and acromegaly. These drugs offer effective symptom control and long-term disease management. Increasing adoption across hospitals and specialty clinics between 2022 and 2026 is driving segment growth. Pharmaceutical companies are focusing on expanding product formulations and improving drug delivery systems to enhance patient compliance and treatment outcomes.

Oral Peptide Delivery Technology Segment to Record Strong Growth

The oral peptide delivery technology segment is expected to witness strong growth due to increasing demand for non-invasive treatment options. Innovations in drug formulation are enabling oral delivery of peptide-based therapies, reducing reliance on injections. Increasing investments in research and development, along with clinical advancements, are accelerating adoption. This technology is expected to transform the treatment landscape by improving patient convenience and accessibility.

Regional Outlook

The global Somatostatin Analogue Drug market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the somatostatin analogue drug market due to advanced healthcare infrastructure and strong adoption of innovative therapies. According to the Pharmaceutical Research and Manufacturers of America, the U.S. leads global pharmaceutical innovation with significant investments in biologics and specialty drugs. Increasing prevalence of chronic diseases and strong regulatory support are driving market growth.

China to Record Strong Growth

China is expected to witness strong growth due to expanding healthcare infrastructure and increasing investment in pharmaceutical manufacturing. According to the World Intellectual Property Organization, China leads in global patent filings, reflecting rapid innovation in healthcare technologies. Government initiatives and rising healthcare expenditure are further accelerating market expansion.

Competitive Landscape

The somatostatin analogue drug market is highly competitive, characterized by strong focus on innovation and specialty drug development. Leading companies such as Novartis AG, Ipsen S.A., Recordati S.p.A., Chiesi Farmaceutici S.p.A., and Crinetics Pharmaceuticals, Inc. are focusing on expanding product portfolios, strengthening clinical pipelines, and enhancing global presence to maintain competitive advantage.

Recent Developments

  • In April 2026, Crinetics Pharmaceuticals, Inc. received European Commission approval for PALSONIFY® (paltusotine) for the treatment of adults with acromegaly, marking the first once-daily oral somatostatin receptor agonist approved in the European Union. The approval was supported by pivotal Phase 3 PATHFNDR studies demonstrating sustained IGF-1 control and symptom reduction, enabling a shift from injectable therapies to oral treatment options. This milestone represents the company’s first regulatory approval outside the U.S., with initial commercialization planned in Germany and Austria, strengthening its global expansion strategy and market positioning in endocrine therapies.
  • In June 2024, Chiesi Farmaceutici S.p.A. (Chiesi Global Rare Diseases) showcased advancements in its endocrine portfolio at the Endocrine Society’s ENDO 2024 meeting, presenting results from Phase 3 clinical trials of MYCAPSSA® (oral octreotide) for acromegaly. The data demonstrated a 72% biochemical response rate along with significant symptom improvement, reinforcing the clinical effectiveness of oral somatostatin therapies. The company also highlighted real-world evidence from the MACRO registry and introduced tools for assessing disease burden, strengthening its position in rare endocrine disease management and supporting its strategy to expand innovative, patient-centric treatment solutions.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global Somatostatin Analogue Drug market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Somatostatin Analogue Drug Market Sales Analysis – Drug Type | Indication | Technology ($ Million)
  • Somatostatin Analogue Drug Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Somatostatin Analogue Drug Market Trends

2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Somatostatin Analogue Drug Market

2.3.1 Competitive Rivalry

2.3.2 Threat of New Entrants

2.3.3 Bargaining Power of Suppliers

2.3.4 Bargaining Power of Buyers

2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Somatostatin Analogue Drug Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Somatostatin Analogue Drug Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Somatostatin Analogue Drug Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Somatostatin Analogue Drug Market Revenue and Share by Manufacturers

  • Somatostatin Analogue Drug Market Size Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 Novartis AG

4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy

4.2.2 Ipsen S.A.

4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy

4.2.3 Recordati S.p.A.

4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy

4.2.4 Chiesi Farmaceutici S.p.A.

4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy

4.2.5 Crinetics Pharmaceuticals, Inc.

4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration

  1. Global Somatostatin Analogue Drug Market Sales Analysis by Drug Type ($ Million)

5.1 Octreotide-based Drugs
5.2 Lanreotide-based Drugs
5.3 Pasireotide-based Drugs
5.4 Emerging/Other Analogues

  1. Global Somatostatin Analogue Drug Market Sales Analysis by Indication ($ Million)

6.1 Acromegaly
6.2 Neuroendocrine Tumors (NETs)
6.3 Cushing’s Disease
6.4 Off-label/Other Indications

  1. Global Somatostatin Analogue Drug Market Sales Analysis by Technology ($ Million)

7.1 Microsphere-based Depot Technology
7.2 Pre-filled Syringe Systems
7.3 Autogel / Deep SC Delivery Systems
7.4 Oral Peptide Delivery Technology

  1. Regional Analysis

8.1 North American Somatostatin Analogue Drug Market Sales Analysis – Drug Type | Indication | Technology ($ Million)

8.1.1 United States
8.1.2 Canada

8.2 European Somatostatin Analogue Drug Market Sales Analysis – Drug Type | Indication | Technology ($ Million)

8.2.1 UK
8.2.2 Germany
8.2.3 Italy
8.2.4 Spain
8.2.5 France
8.2.6 Russia
8.2.7 Rest of Europe

8.3 Asia-Pacific Somatostatin Analogue Drug Market Sales Analysis – Drug Type | Indication | Technology ($ Million)

8.3.1 China
8.3.2 Japan
8.3.3 South Korea
8.3.4 India
8.3.5 Australia & New Zealand
8.3.6 ASEAN Countries
8.3.7 Rest of Asia-Pacific

8.4 Rest of the World Somatostatin Analogue Drug Market Sales Analysis – Drug Type | Indication | Technology ($ Million)

8.4.1 Latin America
8.4.2 Middle East and Africa

  1. Company Profiles

9.1 Amneal Pharmaceuticals, Inc.
9.1.1 Quick Facts
9.1.2 Company Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies

9.2 Apotex Inc.
9.2.1 Quick Facts
9.2.2 Company Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies

9.3 Baxter International Inc.
9.3.1 Quick Facts
9.3.2 Company Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies

9.4 Biocon Ltd.
9.4.1 Quick Facts
9.4.2 Company Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies

9.5 Cipla Ltd.
9.5.1 Quick Facts
9.5.2 Company Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies

9.6 Dr. Reddy’s Laboratories Ltd.
9.6.1 Quick Facts
9.6.2 Company Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies

9.7 Eugia Pharma Specialities
9.7.1 Quick Facts
9.7.2 Company Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies

9.8 Fresenius Kabi AG
9.8.1 Quick Facts
9.8.2 Company Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies

9.9 Gland Pharma Ltd.
9.9.1 Quick Facts
9.9.2 Company Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies

9.10 Hikma Pharmaceuticals PLC
9.10.1 Quick Facts
9.10.2 Company Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies

9.11 Intas Pharmaceuticals Ltd.
9.11.1 Quick Facts
9.11.2 Company Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies

9.12 Lupin Ltd.
9.12.1 Quick Facts
9.12.2 Company Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies

9.13 Meitheal Pharmaceuticals, Inc.
9.13.1 Quick Facts
9.13.2 Company Overview
9.13.3 Product Portfolio
9.13.4 Business Strategies

9.14 Sandoz Group AG
9.14.1 Quick Facts
9.14.2 Company Overview
9.14.3 Product Portfolio
9.14.4 Business Strategies

9.15 Sun Pharmaceutical Industries Ltd.
9.15.1 Quick Facts
9.15.2 Company Overview
9.15.3 Product Portfolio
9.15.4 Business Strategies

9.16 Teva Pharmaceutical Industries Ltd.
9.16.1 Quick Facts
9.16.2 Company Overview
9.16.3 Product Portfolio
9.16.4 Business Strategies

9.17 Viatris Inc.
9.17.1 Quick Facts
9.17.2 Company Overview
9.17.3 Product Portfolio
9.17.4 Business Strategies

9.18 Wockhardt Ltd.
9.18.1 Quick Facts
9.18.2 Company Overview
9.18.3 Product Portfolio
9.18.4 Business Strategies

9.19 Xellia Pharmaceuticals
9.19.1 Quick Facts
9.19.2 Company Overview
9.19.3 Product Portfolio
9.19.4 Business Strategies

9.20 Zydus Lifesciences Ltd.
9.20.1 Quick Facts
9.20.2 Company Overview
9.20.3 Product Portfolio
9.20.4 Business Strategies

1. Global Somatostatin Analogue Drug Market Research and Analysis by Drug Type, 2025–2035 ($ Million) 

2. Global Octreotide-based Drugs Somatostatin Analogue Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

3. Global Lanreotide-based Drugs Somatostatin Analogue Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

4. Global Pasireotide-based Drugs Somatostatin Analogue Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

5. Global Emerging/Other Analogues Somatostatin Analogue Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

6. Global Somatostatin Analogue Drug Market Research and Analysis by Indication, 2025–2035 ($ Million) 

7. Global Somatostatin Analogue Drug Market for Acromegaly Research and Analysis by Region, 2025–2035 ($ Million) 

8. Global Somatostatin Analogue Drug Market for Neuroendocrine Tumors (NETs) Research and Analysis by Region, 2025–2035 ($ Million) 

9. Global Somatostatin Analogue Drug Market for Cushing’s Disease Research and Analysis by Region, 2025–2035 ($ Million) 

10. Global Somatostatin Analogue Drug Market for Off-label/Other Indications Research and Analysis by Region, 2025–2035 ($ Million) 

11. Global Somatostatin Analogue Drug Market Research and Analysis by Technology, 2025–2035 ($ Million) 

12. Global Microsphere-based Depot Technology Somatostatin Analogue Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

13. Global Pre-filled Syringe Systems Somatostatin Analogue Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

14. Global Autogel / Deep SC Delivery Systems Somatostatin Analogue Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

15. Global Oral Peptide Delivery Technology Somatostatin Analogue Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

16. Global Somatostatin Analogue Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

17. North America Somatostatin Analogue Drug Market Research and Analysis by Country, 2025–2035 ($ Million) 

18. North America Somatostatin Analogue Drug Market Research and Analysis by Drug Type, 2025–2035 ($ Million) 

19. North America Somatostatin Analogue Drug Market Research and Analysis by Indication, 2025–2035 ($ Million) 

20. North America Somatostatin Analogue Drug Market Research and Analysis by Technology, 2025–2035 ($ Million) 

21. Europe Somatostatin Analogue Drug Market Research and Analysis by Country, 2025–2035 ($ Million) 

22. Europe Somatostatin Analogue Drug Market Research and Analysis by Drug Type, 2025–2035 ($ Million) 

23. Europe Somatostatin Analogue Drug Market Research and Analysis by Indication, 2025–2035 ($ Million) 

24. Europe Somatostatin Analogue Drug Market Research and Analysis by Technology, 2025–2035 ($ Million) 

25. Asia-Pacific Somatostatin Analogue Drug Market Research and Analysis by Country, 2025–2035 ($ Million) 

26. Asia-Pacific Somatostatin Analogue Drug Market Research and Analysis by Drug Type, 2025–2035 ($ Million) 

27. Asia-Pacific Somatostatin Analogue Drug Market Research and Analysis by Indication, 2025–2035 ($ Million) 

28. Asia-Pacific Somatostatin Analogue Drug Market Research and Analysis by Technology, 2025–2035 ($ Million) 

29. Rest of the World Somatostatin Analogue Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

30. Rest of the World Somatostatin Analogue Drug Market Research and Analysis by Drug Type, 2025–2035 ($ Million) 

31. Rest of the World Somatostatin Analogue Drug Market Research and Analysis by Indication, 2025–2035 ($ Million) 

32. Rest of the World Somatostatin Analogue Drug Market Research and Analysis by Technology, 2025–2035 ($ Million) 

1. Global Somatostatin Analogue Drug Market Share by Drug Type, 2025 Vs 2035 (%) 

2. Global Octreotide-based Drugs Somatostatin Analogue Drug Market Share by Region, 2025 Vs 2035 (%) 

3. Global Lanreotide-based Drugs Somatostatin Analogue Drug Market Share by Region, 2025 Vs 2035 (%) 

4. Global Pasireotide-based Drugs Somatostatin Analogue Drug Market Share by Region, 2025 Vs 2035 (%) 

5. Global Emerging/Other Analogues Somatostatin Analogue Drug Market Share by Region, 2025 Vs 2035 (%) 

6. Global Somatostatin Analogue Drug Market Share by Indication, 2025 Vs 2035 (%) 

7. Global Somatostatin Analogue Drug Market for Acromegaly Share by Region, 2025 Vs 2035 (%) 

8. Global Somatostatin Analogue Drug Market for Neuroendocrine Tumors (NETs) Share by Region, 2025 Vs 2035 (%) 

9. Global Somatostatin Analogue Drug Market for Cushing’s Disease Share by Region, 2025 Vs 2035 (%) 

10. Global Somatostatin Analogue Drug Market for Off-label/Other Indications Share by Region, 2025 Vs 2035 (%) 

11. Global Somatostatin Analogue Drug Market Share by Technology, 2025 Vs 2035 (%) 

12. Global Microsphere-based Depot Technology Market Share by Region, 2025 Vs 2035 (%) 

13. Global Pre-filled Syringe Systems Market Share by Region, 2025 Vs 2035 (%) 

14. Global Autogel / Deep SC Delivery Systems Market Share by Region, 2025 Vs 2035 (%) 

15. Global Oral Peptide Delivery Technology Market Share by Region, 2025 Vs 2035 (%) 

16. Global Somatostatin Analogue Drug Market Share by Region, 2025 Vs 2035 (%) 

17. US Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

18. Canada Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

19. UK Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

20. France Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

21. Germany Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

22. Italy Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

23. Spain Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

24. Russia Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

25. India Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

26. China Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

27. Japan Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

28. South Korea Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

29. Australia & New Zealand Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

30. ASEAN Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

31. Rest of Asia-Pacific Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

32. Latin America Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

33. Middle East & Africa Somatostatin Analogue Drug Market Size, 2025–2035 ($ Million) 

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The market was valued at $5.96 billion in 2025 and is projected to reach $10.22 billion by 2035.
The market is expected to grow at a CAGR of 5.5% between 2026 and 2035.
Octreotide-based drugs dominate due to their widespread clinical use in treating neuroendocrine tumours and acromegaly.
North America leads due to strong healthcare infrastructure and high adoption of advanced therapies.
Oral peptide delivery technology is growing fastest due to increasing demand for non-invasive treatment options.